BioCryst completes Astria Therapeutics acquisition, expanding HAE portfolio.

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics, expanding its leadership in hereditary angioedema (HAE). The deal adds navenibart, a late-stage plasma kallikrein inhibitor, to BioCryst's HAE portfolio. Navenibart has the potential to be the first HAE therapy with every-three and every-six month dosing, significantly improving the treatment experience for HAE patients.